Gilead Sciences (GILD): Reiterate Buy After HIV Expert Dinner - Jefferies

September 12, 2016 7:32 AM EDT
Get Alerts GILD Hot Sheet
Price: $70.95 -0.87%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 29 | Down: 30 | New: 23
Trade GILD Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Gilead Sciences (NASDAQ: GILD) after hosting a dinner with a leading infectious disease specialist involved in the largest provider of HIV care in Boston. The analyst is confident in GILD's HIV life cycle strategies, and despite the existence of competition worth watching, he believes it is likely the company will maintain its HIV revenues LT. In short, the HIV sustainability and potential pipeline upside are underappreciated.

No change to the price target of $91.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $78.05 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Jefferies & Co

Add Your Comment